Form 8-K Cannagistics Inc. For: Aug 01

August 16, 2022 12:50 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
0001304741 false 0001304741 2022-08-01 2022-08-01 0001304741 dei:FormerAddressMember 2022-08-01 2022-08-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares











Date of report (date of earliest event reported): August 1, 2022



 (Exact name of registrant as specified in charter)


Delaware 000-55711 86-3911779
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)


150 Motor Parkway

Suite 401

Hauppauge, NY



(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: 631-787-8455 


 2110 5th Avenue

Ronkonkoma, NY


(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below)


[ ]       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


[ ]       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14-12)


[ ]       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


[ ]       Pre-commencement communications pursuant to Rule 13ed-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act: None.


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company   [ ]


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange.






Item 5.01 Changes in Control of Registrant.


On August 1, 2022, Regen Biowellness, Inc., the holder of 4,400,000 shares of Series F Preferred Voting Stock, entered into an asset purchase agreement with Emergent Health Corp. (“OTCPink “EMGE”) for the purchase of all assets and certain liabilities of Regen Biowellness. The 4,400,000 shares of Series F Preferred Stock of the Registrant which represents voting control over the Registrant.


Therefore, as a result of the asset purchase agreement, there has been a change of control of the Registrant. Emergent Health Corp. is now the holder of the Series F Preferred Stoc, representing voting control of the Registrant.


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Effective as of August 15, 2022, the following individual was removed by a vote of the majority of shares entitled to vote as a Director of the Registrant.


Name   Position
Dr. Babik Ghalili  Director 


Effective as of August 15, 2022, the following resigned as an Officer of the Registrant.


Name   Position
Jim Morrison   President/CEO 


Effective as of August 15, 2022, the following individual(s) were elected by a vote of the majority of shares entitled to vote to the positions indicated of the Registrant:


Name  Age  Position
Jim Morrison   63   Director
James W. Zimbler   58   Director and Interim President/CEO


Mr. Zimbler has served as the Registrant’s Vice President of Corporate Finance since November 2021, and prior was the President. He served as a director of the Company from since November 2017 to November 2021. Previously, from November 17, 2017, until July 1, 2020, he served as President of the Company in which role he was responsible for strategic decision making, capital expenditure planning and staffing matters. From December 2017 until June 2019, he served as President and a director of the predecessor iteration of a public company that is now Enzolytics, Inc., a drug development company. In December 2016 he founded Emerging Growth Advisors, Inc., a consulting firm providing advisory services related to mergers and acquisitions for corporations including the Company, and now Emerging Capital Strategies, Ltd., where he has served as President since formation. Prior to founding Emerging Growth Advisors, Inc., Mr. Zimbler served in a managerial role at other consulting firms, each specializing in mergers and acquisitions, roll ups and turn-around work.  






Item 9.01 Financial Statements and Exhibits


(d) Exhibits


Exhibit No.   Description 
17.1          Letter of Resignation of Jim Morrison as President and CEO, dated August 15, 2022 






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Cannagistics, Inc.


/s/ James W. Zimbler

James W. Zimbler

Interim President/Chief Executive Officer

Date: August 16, 2022








Exhibit 17.1





August 15, 2022





Board of Directors

Cannagistics, Inc.

150 Motor Parkway

Suite 401

Hauppauge, NY 11788


Re:       Cannagistics, Inc. (the “Company”)


Dear Sirs:


Please be advised that I hereby resign as a President/CEO of Cannagastics, Inc., effective the close of business as indicated above.


My resignation does not in any way imply or infer that there is any dispute or disagreement relating to the Company’s operations, policies or practices.




/s/ Jim Morrison

Jim Morrison

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

SEC Filings